Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DXZH | ISIN: FR0013280286 | Ticker-Symbol: EYWN
Tradegate
05.09.25 | 17:08
118,40 Euro
-0,25 % -0,30
1-Jahres-Chart
BIOMERIEUX Chart 1 Jahr
5-Tage-Chart
BIOMERIEUX 5-Tage-Chart
RealtimeGeldBriefZeit
118,00118,9019:03
118,10119,2005.09.

Aktuelle News zur BIOMERIEUX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoBIOMERIEUX: bioMérieux - First-Half 2025 Results4
27.08.J.P. Morgan favors bioMérieux over Diasorin in new coverage call6
26.08.Morgan Stanley favors DiaSorin over bioMérieux in EU biopharma stock shake-up5
26.08.Morgan Stanley downgrades BioMerieux stock rating to Equalweight on valuation2
26.08.Morgan Stanley stuft BioMerieux wegen Bewertung auf "Equalweight" herab5
BIOMERIEUX Aktie jetzt für 0€ handeln
18.08.BIOMERIEUX: bioMérieux receives U.S. 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini5
14.08.bioMerieux faces volatility risk ahead of H1 results, RBC maintains hold3
14.08.RBC: bioMérieux droht Volatilität vor Halbjahreszahlen - Rating bestätigt3
16.06.BIOMERIEUX: bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies9
09.06.Dividendenbekanntmachungen (09.06.2025)7.160 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ALLSTATE CORPORATION  US0200021014  1 USD  0,8776 EUR  ALPHABET INC CL A  US02079K3059  0,21 USD  0,1842 EUR  ALPHABET INC CL C  US02079K1079  0...
► Artikel lesen
03.06.BIOMERIEUX: bioMérieux launches cutting-edge equine infectious respiratory disease testing3
22.05.GXO Logistics: GXO extends longstanding partnership with bioMérieux504PARIS, France, May 22, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world's largest pure-play contract logistics provider, today announced a long-term contract renewal and extension...
► Artikel lesen
07.05.RBC Capital cuts BioMerieux stock rating on FX, tariff concerns6
22.04.BIOMERIEUX: WATCHFIRE by bioMérieux: a PCR test to detect viruses and bacteria in wastewater and respond to potential infectious disease outbreaks3
17.04.BIOMERIEUX: bioMérieux - First-Quarter 2025 Business Review5
07.04.BIOMERIEUX: bioMérieux obtains CE-marking for LUMED APSS, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship3
24.03.BIOMERIEUX: Release of the Universal Registration Document including the Annual Financial Report as of December 31, 20242
18.03.bioMérieux receives FDA 510(k) Clearance for its VITEK COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance687MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration...
► Artikel lesen
03.03.QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology1.086PARIS (dpa-AFX) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements...
► Artikel lesen
07.11.24Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com1.087The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1